NgoJuni ka-2020, uvavanyo lwe-REREVERY oluvela kwiqela labaphandi kwiYunivesithi yaseOxford e-UK baxela ukusetyenziswa kwedexamethasone enexabiso eliphantsi.1 kunyango lwezigulane ezigula kakhulu ze-COVID-19 ngokunciphisa ukudumba. Kutshanje, ichiza elisekelwe kwiprotheni, elibizwa ngokuba yi-Aviptadil, liye lalandelelwa ngokukhawuleza yi-FDA ngokwenza ulingo lwezonyango ngokumodareyitha ukuya. kakhulu izigulana ze-COVID. Ityala laqala ngo-1st NgoJulayi 2020 kunye neziphumo zokuqala ziyakhuthaza kakhulu.
Ugqatso lusekuphuhliseni amachiza akhuselekileyo nasebenzayo kunyango lwe Covid-19, eye yasokolisa ihlabathi liphela kwaye yabangela imicelimngeni ebalulekileyo yezoqoqosho kunye nezempilo kumazwe angaphezu kwama-200 kwihlabathi jikelele. Nangona i-molecule encinci ye-anti-viral iziyobisi zivunyiwe njengomlinganiselo wokulungisa, kukho iziphumo ezichaphazelekayo ezichaphazelekayo zala machiza amancinci. Kuzingelwe amayeza athile asekelwe kwiprotheyini aquka izilwa-buhlungu ze-monoclonal2 ezithe ngqo ngakumbi kwaye zineziphumo ebezingalindelekanga ezincinci. Ukongeza, kwimbono yexesha elide yokukhusela abemi behlabathi, umhlaba wonke ulinde ngomdla isitofu esikhuselekileyo nesisebenzayo esiya kunceda ukuphuhlisa ukunganyangeki okusebenzayo ngokuchasene nentsholongwane kunye nokubuyisela ubomi kwimeko yesiqhelo njengoko kwakunjalo ngaphambi kwe-COVID-19.
I-Aviptadil yinkqubo yokwenziwa kweVasoactive Intestinal Polypeptide (VIP). I-VIP yafunyanwa okokuqala ngo-1970 nguGqr Sami Said, ingcali yamayeza emiphungeni. Ikhoyo kwiindawo eziphezulu kwimiphunga apho ibandakanyeka ekuphumleni kweendlela zomoya kunye nemikhumbi ye-pulmonary. I-VIP ichongiwe njengeyona nto inamandla yokuchasa ukudumba, esebenza ngokulawula ukuveliswa kwababini abalamli abachasayo kunye ne-pro-inflammatory.3 kunye nemisebenzi ngokuthintela i-cytokines evuthayo.
Ukusetyenziswa kwe-Aviptadil kulingo lwezonyango olusanda kuvunywa kuye kwakhokelela ekubuyiselweni ngokukhawuleza kwezigulana ekungaphumeleli kokuphefumla kwizigulana ze-Covid-19 ezigula kakhulu. Ekusebenziseni iyeza, lasusa ukudumba kwemiphunga yabo, laphucula amanqanaba eoksijini yegazi labo kwaye lanciphisa iimpawu zokukrala ngaphezulu kwe-50% kwizigulana ezingaphezu kwe-15.4. Nangona kunjalo, idatha eyongezelelweyo evela kwilingo leklinikhi iyadingeka ukuseka ukhuseleko kunye nokusebenza kakuhle kwe-Aviptadil kwinani elikhulu lezigulane ezibandakanya izigulane ezinobunzima obuncinci bokugula ukuqinisekisa ukuba ukuqwalaselwa okufanayo kubonakala.
***
Iingxelo:
- Soni, R, 2020. I-Dexamethasone: Ngaba izazinzulu zilufumene unyango lwe-COVID-19 eZigula kakhulu? Inzululwazi yaseYurophu. Ipapashwe ngo-Agasti 14, 2020. Iyafumaneka kwi-intanethi https://www.scientificeuropean.co.uk/covid-19/dexamethasone-have-scientists-found-cure-for-severely-ill-covid-19-patients/
- Soni, R, 2020. Ii-Monoclonal Antibodies kunye ne-Protein Based Drugs zinokusetyenziselwa ukuNyanga i-COVID-19. Inzululwazi yaseYurophu. Ipapashwe ngo-Agasti 14, 2020. Iyafumaneka kwi-intanethi https://www.scientificeuropean.co.uk/covid-19/monoclonal-antibodies-and-protein-based-drugs-could-be-used-to-treat-covid-19-patients/
- I-Delgado M, i-Abad C, i-Martinez C, i-Juarranz MG, i-Arranz A, i-Gomariz RP, i-Leceta J. I-peptide ye-intestinal ye-Vasoactive kwi-immune system: indima enokubakho yonyango kwizifo ezivuthayo kunye ne-autoimmune. J Mol Med (2002) 80:16-24. DOI: https://doi.org/10.1007/s00109-001-0291-5
- Youssef JG, Zahiruddin F, Al-Saadi M, Yau S, Goodarzi A, Huang HJ, Javitt JC. Ingxelo emfutshane: UkuBuyiswa okuKhawulezayo kweKlinikhi kwi-Critical COVID-19 kunye nokusilela ekuPhumleni kwiSigulana soTshintsho lwemiphunga esinyangwa nge-Intravenous Vasoactive Intestinal Peptide. Ukuprintwa kwangaphambili 2020, 2020070178 DOI: https://doi.org/10.20944/preprints202007.0178.v2
***
